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V I R O L O G Y
Heteromultivalent topology-matched  
nanostructures as potent and broad-spectrum  
influenza A virus inhibitors
Chuanxiong Nie1,2, Marlena Stadtmüller2, Badri Parshad1,3, Matthias Wallert1,  
Vahid Ahmadi1, Yannic Kerkhoff1, Sumati Bhatia1, Stephan Block1*, Chong Cheng4*, 
Thorsten Wolff2*, Rainer Haag1*
Here, we report the topology-matched design of heteromultivalent nanostructures as potent and broad-spectrum 
virus entry inhibitors based on the host cell membrane. Initially, we investigate the virus binding dynamics to 
validate the better binding performance of the heteromultivalent moieties as compared to homomultivalent 
ones. The heteromultivalent binding moieties are transferred to nanostructures with a bowl-like shape matching 
the viral spherical surface. Unlike the conventional homomultivalent inhibitors, the heteromultivalent ones ex-
hibit a half maximal inhibitory concentration of 32.4 ± 13.7 g/ml due to the synergistic multivalent effects and 
the topology-matched shape. At a dose without causing cellular toxicity, >99.99% reduction of virus propagation 
has been achieved. Since multiple binding sites have also been identified on the S protein of SARS-CoV-2 (severe 
acute respiratory syndrome coronavirus 2), we envision that the use of heteromultivalent nanostructures may also 
be applied to develop a potent inhibitor to prevent coronavirus infection.
INTRODUCTION
The fast development of broad-spectrum solutions to prevent and 
inhibit viral infections is of great societal need. COVID-19 (coronavirus 
disease 2019), which is caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), has become a global health problem, 
with tens of millions of infections and hundreds of thousands of 
fatalities by now (1, 2). Besides SARS-CoV-2, influenza A virus (IAV) 
is also a highly infectious pathogen circulating in human beings and 
many other kinds of animal species (3, 4). Because of a high error 
rate of the viral RNA polymerase, human IAV evolution is accom-
panied by unpredictable antigenic drift and may involve the acqui-
sition of mutations conferring resistance to many current antivirals 
(5, 6). Therefore, methods to develop potent and broad-spectrum 
viral inhibitors to quickly respond to the unexpected outbreak are 
urgently required (7, 8).
The viral infection cycle begins with binding to the receptors on 
the host cell membrane. Therefore, inhibiting viral entry via a binding 
decoy has been proved to be effective for many types of viruses, e.g., 
the use of multivalent mannose structures is reported to be effective 
for inhibiting Ebola virus infection, which is one of few options to 
fight Ebola infection (9–12). For IAV, two glycoproteins have been 
identified to be associated with the binding behavior on the cellular 
membrane, hemagglutinin (HA) and neuraminidase (NA). The multi-
valent binding between HA and sialic acid receptors on the host cell 
triggers the viral entry. Therefore, polysialylated structures with syn-
thetic scaffolds have been designed for IAV inhibition (13–15). However, 
as the HA binding pocket varies in different IAV strains, developing 
broad-spectrum IAV inhibitors is a challenge. Intertrimer targeting 
that covers all the strain variations and subtypes of the IAV HA pro-
teins can hardly be achieved with a single synthetic polysialyated 
structure. However, this task might be accomplished by cellular 
membrane–based materials. The cellular membrane is a highly stable 
self-assembled structure with a native display of virus-binding re-
ceptors. In principle, the native cell membrane can be a robust IAV 
binder, as it has the complex, dynamic, and multivalent sialic acid 
display for the binding of various IAVs. Moreover, the extraction of 
the cellular membrane is easier than synthesizing multivalent nano-
structures matching the sialic acid–binding pockets on HA.
NA acts as a sialidase to cleave sialic acid from the attached host 
cell surface for the release of progeny virions. As a result of the HA-NA 
interplay, the interactions between IAV and host cells are transient 
and need to be dynamically balanced during early and late time points 
of infection, respectively (16, 17). Therefore, for the potent inhibi-
tion of both HA and NA, the heteromultivalent nanostructures are 
required to block both proteins. This is, however, rarely achieved, as 
most of the current antiviral strategies rely on homomultivalent en-
gagement of HA (13, 14, 18). Here, we aim for generating a highly 
potent IAV inhibitor by combining three different bioinspired de-
sign incentives: (i) coating the inhibitor surface with a cell-derived 
membrane that serves as a native source of sialic acids (Fig. 1A); (ii) 
complementing the cell-derived membrane with zanamivir (Zan), an 
approved NA inhibitor, that enhances the IAV-membrane interaction 
by heteromultivalent binding (Fig. 1B); and (iii) using a concave inhib-
itor topology-matched shape that further enhances the IAV-membrane 
interaction by maximizing the total interaction area (Fig. 1C).
RESULTS
Red blood cell membrane as a potent binder but not 
inhibitor toward IAV
As most of the human IAV strains bind to red blood cells (RBCs) 
actively, we first investigated whether membranes extracted from 
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RBCs are efficient IAV binders. Vesicles made of RBC membranes 
(RBCm) are obtained by disrupting human RBCs and centrifugation, 
and the obtained RBCm vesicles have the same protein presentation 
to the RBCs (fig. S1). The binding between RBCm and IAVs is in-
vestigated by an assay based on total internal reflection fluorescence 
(TIRF) microscopy (Fig. 1D) (19). The ganglioside GD1a-containing 
supported lipid bilayer (SLB) is created at a glass interface, and TIRF 
microscopy is used to monitor the transient binding of IAVs to this 
SLB. Subsequent application of single-virus tracking allows for ex-
tracting various information about the multivalent IAV–sialic acid 
interaction, the IAV attachment to the sialic acid–containing SLB, 
and the IAV mobility and off-rate distributions (19).
A decrease in the IAV attachment rate for increasing RBCm ves-
icle concentration is observed, indicating that RBCm vesicles can bind 
with IAVs and block their interaction with GD1a. The IC50TIRF (half 
maximal inhibitory concentration from TIRF) value from this mea-
surement is 2.9 ± 1.2 g/ml. From the hemagglutination inhibition 
assays of A/X31 (H3N2), A/Panama/2007/1999 (H3N2), A/PR/8/34 
(H1N1), and A/Bayern/63/2009 (H1N1pdm), the broad-spectrum 
IAV binding ability of the RBCm vesicles is confirmed with an inhi-
bition constant (KiHAI) in the nanomolar range (Table 1). The cellular 
infection assay, where the Madin-Darby canine kidney II (MDCK-II) 
cells, an epithelial host cell for IAV infection derived from canine 
kidney, are infected by influenza A/X31 (H3N2) in the presence of 
RBCm vesicles (100 g/ml), revealed the broad-spectrum inhibition 
potential of the RBCm vesicles. However, the inhibitory activity of 
RBCm vesicle is not ideal; only a small decrease in infected cells is 
noticed, as shown in Fig. 1E. The reduction of virus titer for RBCm 
vesicles is two orders of magnitude (Fig. 1F).
 It should be noted that the sialic acids for RBCm can be different 
from those for MDCK-II cells, especially the glycan structures (20, 21). 
The membrane of MDCK-II cells is obtained, and its binding to 
influenza A/X31 (H3N2) is studied via hemagglutination inhibition 
assays. The MDCK-II cell membrane exhibits a KiHAI of 1.6 ± 0.5 nM, 
which is lower than that of RBCm in the same assay (8.4 ± 4.2 nM). 
As a binding decoy, the binding to the inhibitor should outperform 
the binding to the actual receptor to achieve potent inhibition (22). 
When applying RBCm to MDCK-II cells, the virions may still bind 
to the actual sialic acid receptor on MDCK-II cells because of the 
higher binding affinity and then start the infection. Therefore, to 
develop a potent IAV inhibitor with RBCm, the virus binding ability 
must be further improved.
Heteromultivalent surface for enhanced virus binding
Two concepts are introduced for improving the virus binding abili-
ty of RBCm: (i) supplementing additional NA inhibitors to further 
Fig. 1. Design of heteromultivalent topography-matching nanostructures for virus inhibition. (A and B) Design and synthesis of a heteromultivalent nanobowl 
(Hetero-MNB) for IAV inhibition, including the coating of red blood cell membranes (RBCm) onto the NB surface and the further modification with lipidic Zan. (C) Proposed 
binding patterns between IAV and the Hetero-MNB, where sialic acid and Zan bind to HA and NA, respectively, and the bowl shape with facilitating the capping to the 
surface of the virus particle. (D) Inhibition curves for RBCm vesicles at different concentrations from a TIRF setup. Values are expressed as means ± SD, n = 4. (E) Typical 
immunofluorescent staining images of viral nucleoprotein (NP) to show the infected cells with the treatment of RBCm vesicles. Scale bars, 50 m. Multiplicity of infection, 
0.1. DAPI, 4′,6-diamidino-2-phenylindole. (F) Propagation of IAV in the presence of RBCm vesicles. Values are expressed as means ± SD, n = 4. PFU, plaque-forming units.
Table 1. Inhibition constants of RBCm vesicles of different IAV strains 
from hemagglutination inhibition assay. Values are expressed as 
means ± SD, n = 4. 
KiHAI (g/ml) KiHAI (nM sialic acid)
A/X31 (H3N2) 41.6 ± 20.6 8.4 ± 4.2
A/PR/8/34 (H1N1) 23.4 ± 9.0 4.8 ± 1.8
A/Panama/2007/1999 
(H3N2)
27.3 ± 7.8 5.5 ± 1.7
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promote the viral binding to the RBCm and (ii) transferring the 
RBCm to a nanoparticle surface with matched topology to the IAV 
virion to maximize the interaction area (Fig. 1, B and C). To prove 
the first concept that heteromultivalent targeting of both HA and 
NA on IAV can further promote virus binding, hybrid vesicles of 
RBCm with an approved NA inhibitor, Zan, are obtained. Zan is 
initially covalently coupled to lipid and then formed into a lipid ves-
icle (figs. S2 and S3). The hybrid RBCm-Zan vesicle is obtained via 
cosonication. The binding of IAV virions to the vesicles is checked 
by hemagglutination inhibition assays (Table 2). The addition of free 
Zan decreases the KiHAI value for RBCm vesicles, indicating that 
inhibiting NA can improve virion binding due to the inhibition of 
HA–sialic acid cleavage. The NA activity for RBCm-Zan–treated 
virions is similar to those treated by “RBCm + Free Zan” (fig. S4), 
but a lower KiHAI value is noticed. This means that besides the 
NA inhibitory activity, Zan may also provide an additional bind-
ing possibility for the virion, which is analyzed in detail via TIRF 
microscopy using single-virus tracking and the equilibrium fluctua-
tion analysis (23, 24).
 The TIRF-based assay is now operated using SLBs that have been 
fused with RBCm vesicles, Zan-conjugated lipids, or a mixture of 
both, allowing to determine changes in the IAV binding dynamics 
that are caused by the presence of different glycostructures (RBCm- 
originating sialic acid, Zan-conjugated lipids, or a combination of 
both; Fig. 2). In this analysis, RBCm vesicles are fused with POPC 
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)–based vesicles, 
allowing to form “hybrid” SLBs containing RBCm material and serving 
as a homomultivalent structure (25, 26). A heteromultivalent SLB 
membrane is generated by incorporating lipidic Zan into the RBCm 
hybrid SLB (RBCm-Zan).
Application of the TIRF assay indicates that the rate of IAV at-
tachment to the heteromultivalent surface of RBCm-Zan shows 
threefold higher values with respect to Zan- or RCBm-SLB (Fig. 2B). 
Furthermore, single-virus tracking also provides information about 
the motion of IAV while being SLB bound. On RBCm-SLBs, most 
of the mobile tracks are very short, indicating that the viruses stay at 
the surface for less than 1 s before being released (Fig. 2C, fig. S5A, 
and movie S1). This behavior is qualitatively similar to IAVs inter-
acting with GD1a-containing SLBs (19). The addition of Zan-conjugated 
lipids, however, strongly increases the duration of the mobile popula-
tion, which now exhibits very long tracks, and thus the IAV residence 
time being much larger than 1 s (Fig. 2C, fig. S5B, and movie S2). 
This behavior is observed for both membranes, the homomultivalent 
Zan-SLBs and the heteromultivalent RBCm-Zan-SLB. Hence, while 
IAVs show only short residence times to sialic acid–containing SLBs, 
the NA-Zan interaction generates very large IAV residence times to 
Zan-containing SLBs. These findings are in line with the observa-
tion that the binding between Zan and NA is predominant to the 
binding between sialic acid and IAV (27) and with the concept that 
the inhibitory effect of Zan on NA plays a beneficial role for perma-
nent binding, as NA is able to cleave the binding between HA and 
sialic acid as sialidase. Hence, while a notable fraction of IAVs ex-
hibit only short residence times to sialic acid–containing SLBs and 
can, therefore, bind to a small number of sialic acids, the addition of 
lipid-Zan strongly extends the IAV residence time by the formation 
of NA-Zan interactions. In the heteromultivalent SLB, this behavior 
keeps the IAVs sufficiently long at the membrane to allow for bind-
ing a large number of sialic acids, thereby promoting the IAV at-
tachment rate and IAV entrapment by the membrane. Thus, the 
heteromultivalent membrane provides a much better binding com-
pared to homomultivalent ones.
Nanobowl with a matched surface toward IAV virion 
for virus binding
To prove the second concept that matching topology can benefit the 
virus binding, bioinert and biostable nanoparticles with sphere [nano-
sphere (NS)] and bowl-like [nanobowl (NB)] morphologies are 
synthesized, as shown in Fig. 3A and figs. S6 and S7 (28). The nano-
particle is homomultivalently coated with RBCm (figs. S8 and S9), 
named as NS-RBCm and NB-RBCm, respectively. The coating is 
carried out via cosonicating an RBCm vesicle with NS and NB 
(29, 30). A cellular membrane is a highly dynamic lipid system with 
Table 2. Inhibition constants of samples against A/X31 (H3N2) from 
hemagglutination inhibition assay. Values are expressed as means ± SD, 
n = 4. 
KiHAI (g/ml) KiHAI (nM sialic acid)
RBCm 41.6 ± 20.6 8.4 ± 4.2
MDCK-II membrane 6.8 ± 1.9 1.6 ± 0.5
RBCm vesicles and 
 free Zan
11.7 ± 4.5 2.4 ± 0.9
RBCm-Zan hybrid 
vesicles
5.9 ± 2.3 1.2 ± 0.5
NB-RBCm 51.9 ± 23.8 3.1 ± 1.4
NB-RBCm and Zan 19.5 ± 7.8 1.2 ± 0.5
Hetero-MNB 13.7 ± 3.9 0.8 ± 0.2
Fig. 2. Heteromultivalent surfaces for the interaction with IAV virions. (A) TIRF- 
based assay for assessing the interaction of IAVs with homo- or heteromultivalent 
membranes. The corresponding glycostructures (either sialic acids or lipid-conjugated 
Zan) are incorporated in an SLB, and the IAV-SLB interaction is recorded using TIRF 
microscopy. Application of single-virus tracking allows for extracting changes of 
(B) the rate of IAV attachment to the membranes and (C) the motion of SLB-bound 
IAVs, when using the different homo- and heteromultivalent structures. Each color 
represents the track of a single virion. Values in (B) are expressed as means ± SEM, 
n = 10. **P < 0.01 and ***P < 0.001 by Student’s t test. Note the different scale bars 
used for the immobile and mobile IAVs in (C).
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the ability to deform and adapt to the surrounding environment. In 
the coating process, the high-power sonication drives the membrane 
vesicle to follow the curvature of the NB. After the sonication, the 
membrane is stabilized on the surface of the nanoparticle via hydro-
phobic interactions. Last, free membrane vesicles are removed by 
centrifugation.
The prototypic IAV virion is a nanosized sphere around 100 nm 
in diameter, and in our synthesis, an NB with a concave structure of 
around 120 nm is selected, as it matches the size of the IAV to benefit 
multivalent interactions (Fig. 3A). The binding for the NS-RBCm 
and NB-RBCm is studied by a prophylactic infective assay (fig. S10). 
Less infected cells and higher cell viability are noticed for NB-RBCm 
than for NS-RBCm. The IC50infection inhibition value for NB-RBCm is 
about four times lower than that of NS-RBCm, as shown in Fig. 3B. 
The better inhibition by the NB-RBCm should be attributed to its 
matched shape to the IAV virion, which can promote the binding of 
the virus, as proved by our binding test in fig. S11.
Geometry analysis of the virus binding to NS-RBCm and NB-RBCm 
is performed with the model of a convex virion binding to a convex 
or concave inhibitor, respectively, as shown in Fig. 3C. The IAV vi-
rion is illustrated as a particle of around 100 nm. The steric shield-
ing by the inhibitor is estimated by placing inhibitors with the same 
curvature, which are marked with dashed lines (31). The actual 
contact between the virion and the inhibitor is marked white with 
an angle of θ1, while the steric shielding by the inhibitor is marked 
purple with an angle of θ2. In these two cases, the actual contact area 
is quite similar, but the steric shielding is different. A concave inhib-
itor creates a much larger steric shielding than a convex inhibitor; 
therefore, it shows better virus inhibition than the convex one. An-
other difference between them is the edge distance. The concave 
inhibitor is much closer to the virion than the convex one. Monova-
lent sialic acid–HA interaction is weak with a dissociation constant 
of 1 to 20 mM (17, 32). When binding to a surface, e.g., cellular mem-
brane, the virion remains mobile in the beginning. This is what we 
have observed from TIRF that IAV virions remain mobile when bind-
ing to RBCm. The virion is transiently interacting with RBCm and 
then stabilizes on the surface via multivalent interactions. Many other 
studies also reported that influenza virions are mobile when bind-
ing at the biological interfaces (17, 33–35). Therefore, we presume 
that in the case of a convex inhibitor (NS), a virion could be released 
by crawling and gliding, especially when NA is constantly cleaving 
the sialic acid–HA interaction. For a concave inhibitor (NB), the small 
edge distance enables a virion to more easily recruit binding ligands 
for multivalent interaction and subsequent stabilization.
Heteromultivalent NB as a potent and broad-spectrum  
IAV inhibitor
Last, concepts (i) and (ii) are combined into a heteromultivalent NB 
(Hetero-MNB) for the in vitro viral inhibition studies, which is ob-
tained by inserting the lipid-Zan to NB-RBCm. The negatively stained 
high-resolution transmission electron microscopy (HR-TEM) im-
ages in Fig. 3D reveal the binding between IAV virion and Hetero- 
MNB. The hemagglutination inhibition assay (Table 2) reveals that 
the Hetero-MNB is more predominant than NB-RBCm for viral 
binding. As a result of heteromultivalent inhibition of HA and NA, 
the IAV virion binding to MDCK-II cells is notably inhibited, as 
shown in Fig. 4 (A to C). Little-to-no virus particles are detected on 
the surface of MDCK-II cells by flow cytometry and fluorescence 
microscopy, indicating that the inhibitors can effectively block the 
entry of the virus.
Fig. 3. Topography-matching principle for maximized virus interaction. (A) High-resolution transmission electron microscopy (HR-TEM) images for NS and NB with 
RBCm coating. Scale bars, 50 nm. (B) IC50infection inhibition values for the homomultivalent NS-RBCm and NB-RBCm. Values are expressed as means ± SD, n = 4. (C) Geometry 
analysis for a virion binding to a convex inhibitor and concave inhibitor. The actual contact between them is marked with θ1; the steric shielding by the inhibitor is marked 
with purple lines with θ2. Steric shielding is estimated by placing inhibitors with the same curvature. (D) Negatively stained HR-TEM image for the IAV particle binding with 
the Hetero-MNB. Scale bar, 50 nm. Images for other samples are shown in fig. S11.
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Next, we investigated whether the Hetero-MNB is able to inhibit 
the virus infection at the entry step by counting cells expressing IAV 
nucleoprotein (NP) (Fig. 4, D and E, and figs. S12 and S13). The 
treatment of NB-RBCm and Hetero-MNB significantly reduces the 
infectivity of A/X31 (H3N2), and Hetero-MNB shows better inhib-
itory effects than NB-RBCm. We have tested the inhibition toward 
four typical human IAV strains [A/X31 (H3N2), A/PR/8/34 (H1N1), 
A/Panama/2007/1999 (H3N2), and A/Bayern/63/2009 (H1N1pdm)]. 
The Hetero-MNB shows broad-spectrum inhibition, as little-to-no 
infected cells are observed in these four tests. The cell viability test 
further verifies the inhibitory effects of Hetero-MNB (Fig. 4E), where-
as the cells are more viable after the treatment by Hetero-MNB. Here, 
Hetero-MNB reveals an IC50infection inhibition value of 32.4 ± 13.7 g/ml. 
It should be noted that Hetero-MNB shows no clear toxicity in MDCK- 
II cells (fig. S14). The CC50 (50% cytotoxic concentration) value is 
2.4 ± 0.5 mg/ml, corresponding to a selective index of 74.1.
In addition to the cellular infections, the ability to reduce viral 
propagation is also studied by plaque assay for the samples, as shown 
in Fig. 4G. In this test, to investigate whether they can be used as a 
therapeutic agent, the inhibitors are used after the cells have been 
infected by the virus. Both the NB-RBCm and Hetero-MNB reduced 
viral titers. Hetero-MNB outperforms the homomultivalent ones with 
four orders of magnitude of reduction, which corresponds to inhib-
itory effects higher than 99.99%. Figure 4H further illustrates that the 
Hetero-MNB is active against the typical IAV strains circulating in 
humans, revealing its potential to be a broad-spectrum IAV inhibitor.
IAV mutation with Zan resistance has been noticed recently 
(36, 37). We also tested Hetero-MNB for the inhibition of a Zan- 
resisting strain (influenza A/BLN/28/2012) via cellular infection assays 
(fig. S15) (38). Hetero-MNB can inhibit viral replication with two 
orders of magnitude reduction of virus titer. However, in this case, 
because NA has mutated, NB-Zan does not show any inhibitory ef-
fects; Hetero-MNB and NB-RBCm show similar activities. Consid-
ering the inhibitory effects of RBCm, NB-RBCm and Hetero-MNB 
can be one possible solution to inhibit Zan-resisting IAV strains. 
The use of Zan is a proof of concept for heteromultivalency; other 
NA inhibitors (e.g., oseltamivir and NA antibodies) may also be used 
for heteromultivalency via similar methods (39–41).
Fig. 4. Inhibition of IAV infection by the heteromultivalent topography-matching nanostructure. (A) Flow cytometry for the virus attachment to MDCK-II cells and 
(B) corresponding mean and median fluorescence intensities (FI) for the samples. The error bars are generated by the CytExpert Acquisition and Analysis Software Version 
2.3. Fluorescence intensity is measured in arbitrary units. (C) Projection confocal laser scanning microscopy images for the viral attachment to MDCK-II cells in the presence 
of Hetero-MNB. Scale bars, 20 m. (D) Typical immunofluorescence images to show the IAV [A/X31 (H3N2)] infection in the presence of the inhibitors. Other images are 
shown in figs. S12 and S13. Scale bars, 100 m. (E) Detection of viral NP in cells infected with four typical human IAV strains, including A/X31 (H3N2), A/PR/8/34 (H1N1), A/
Panama/2007/1999 (H3N2), and A/Bayern/63/2009 (H1N1pdm) in the presence or absence of inhibitors. (F) Inhibition of A/X31 (H3N2) of the inhibitors at different dosag-
es revealed by cell viability. (G) Inhibition toward IAV propagation [A/X31 (H3N2)] for the inhibitors. (H) Inhibition toward IAV propagation for the inhibitors against 
three other IAV strains, including A/PR/8/34 (H1N1), A/Panama/2007/1999 (H3N2), and A/Bayern/63/2009 (H1N1pdm). The inhibitors are used after the first cycle of infec-
tion. Inhibitor dosage, 100 g/ml. Values are expressed as means ± SD, n = 4. *P < 0.05, **P < 0.01, and ***P < 0.001 by Student’s t test, respectively.
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The inhibitory activity of RBCm-based structures might be lower 
than the one of recently reported, rationally designed polysialylated 
structures (14, 15, 42), but compared with their complicated syn-
thetic process and high costs, the approach in this study is much 
simpler, sparing the efforts of preparing and screening a big library 
of candidate compounds. If a mutation that IAV requires a different 
sialic acid density occurs, then the synthetic structures with the fixed 
sialic acid display may lose their activity. Membrane-based com-
pounds may be less prone to this pitfall since membrane fluidity and 
the possibility of lateral diffusion of membrane proteins enable at-
tachment factors to adjust and possibly even be recruited by virions 
as needed. The easy preparation of RBCm-based inhibitors makes it 
an excellent candidate to prepare in case they do lose activity after 
all. Even if IAV acquires mutations to not bind RBC anymore, we 
still have the option of taking the membrane from its host cells, e.g., 
A549 cells and MDCK-II cells for inhibitor development. It should 
be noted that the extraction of A549 and MDCK-II cell membranes 
takes more effort and needs further optimization for large-scale 
production.
DISCUSSION
The development of heteromultivalent RBCm inhibitors with a 
topology-matched design is believed to expand the toolbox for fight-
ing pathogens as alternatives for the rapidly emerging resistance to 
the current drugs and therapies. In our study, the combination of 
the specific binding capabilities of sialic acid and Zan provide a 
unique heteromultivalent dynamic viral binding decoy to achieve 
potent interactions with IAV, which is much better than the con-
ventional homomultivalent ones. When coated onto a fitting bowl-
shaped nanostructure, the heteromultivalent membrane exhibits 
99.99% viral inhibition due to the synergistic multivalent effects and 
topology- matched shape at a dose, causing no cellular toxicity. The 
IC50infection inhibition value is 32.4 ± 13.7 g/ml (1.8 ± 0.8 nM sialic acid) 
with a selective index of 74.1. We also proved that Hetero-MNB could 
serve as a broad-spectrum binding decoy and entry inhibitors for 
human IAV strains.
Furthermore, this unique strategy using bioinspired heteromulti-
valent topology-matching nanostructures is a general approach to fabricate 
broad virus inhibitors and might compete with previously unknown or 
mutated viruses better than specifically designed drugs. Recent studies 
have pointed out the in vivo safety of RBCm-coated nanoparticles, 
of which the intravenous injection does not induce any adverse ef-
fects in mice (29, 43). They have been used for the development of 
an in vivo drug delivery vehicle, toxin absorber, and vaccine plat-
form (43–45). The potential antigenicity of a foreign cell membrane 
can be addressed by taking the RBCs from the host. The protocol for 
membrane extraction is simple and can be finished within 1 day. 
Therefore, it is believed that cell membranes can serve as a promis-
ing platform to develop virus inhibitors.
There are many similarities between SARS-CoV-2 and IAV, not 
only in disease symptoms but also in the infection cycles. SARS-CoV-2 
uses its spike protein (S protein) to interact with the angiotensin- 
converting enzyme 2 (ACE2) on host cells’ surface to mediate cellular 
entry. Structural analysis of S protein has revealed several binding 
sites for potential inhibitor design (46, 47). On the head of S protein 
(S1 domain) locates the receptor binding domain (RBD) that inter-
acts with ACE2. The stalk domain (S2 domain) contains a fusion 
peptide that triggers the virus fusion with host cells to release the 
viral genome for replication. A furin cleavage site is identified at the 
S1/S2 region, the cleavage of which, by furin or TMPRSS2, might 
contribute to activate RBD interaction with ACE2. It has also been 
revealed by a recent study that these domains can be targeted sepa-
rately by noncompeting antibodies. Antibody cocktails showed a 
substantially improved virus neutralization ability compared to mon-
ovalent antibodies (48, 49). Taking together the information from 
this study, it is believed that the heteromultivalent display of ligands 
that target different domains on S proteins can result in a potent 
SARS-CoV-2 inhibitor (50, 51). The membrane of the host cells, e.g., 
Vero E6 cell, may be used as one target to the RBD (52). For the 
design of such an inhibitor, the platform supporting the ligands 




All chemicals and solvents are of high-performance liquid chroma-
tography or reagent grade and purchased from Sigma-Aldrich 
(Steinheim, Germany) unless stated otherwise. The deionized water 
(minimum resistivity of 18.0 megohms∙cm) is obtained from a 
Millipore water purification system. The human RBCs are obtained 
from Haema Blutspendezentrum, Berlin, Germany. Characteriza-
tion methods are listed in the Supplementary Materials.
Viruses and cells
MDCK-II epithelial cells are maintained in monolayer cultures in 
Dulbecco’s modified Eagle’s medium (DMEM) [with 10% fetal calf 
serum, 2 mM l-glutamine, streptomycin (100 mg/ml), and penicil-
lin (100 U/ml)] at 37°C and 5% CO2. IAV strains A/Panama/2007/1999 
(H3N2), A/X31 (H3N2), A/PR/8/34 (H1N1), A/Bayern/63/2009 
(H1N1), and A/BLN/28/2012 are taken from the strain collection of 
Unit 17 at the Robert Koch-Institut (Berlin, Germany) and propa-
gated in 10-day-old embryonated chicken eggs. The stock virus is 
quantitated by plaque titration on MDCK-II cells.
Extraction of RBCm
The RBCm is obtained by a hypotonic treatment and ultracentrifu-
gation process. The human RBCs are first washed with phosphate- 
buffered saline (PBS) (pH 7.4) at 4°C to remove the residual platelets 
and blood proteins and then treated overnight with deionized water–
diluted PBS buffer (0.25×) at 4°C. The RBCm is collected by 5-min 
centrifugation at 10, 000 rpm, then washed with PBS buffer exten-
sively, and then frozen at −20°C for storage.
Extraction of MDCK-II cell membrane
The membrane of MDCK-II cells is extracted according to earlier 
protocols (53, 54). The MDCK-II cells are harvested by trypsin and 
collected by 5-min centrifugation at 1000 rpm. The cells are washed 
three times with PBS and then placed in cold tris buffer (pH 7.4) con-
taining 10 mM tris, 10 mM MgCl2, and 1× EDTA-free protease in-
hibitor. The cells are then disrupted by homogenizing with a dounce 
homogenizer on ice. The solution is centrifuged at 5000 rpm for 5 min; 
the supernatant containing membrane vesicles is then centrifuged 
at 100,000g for 2 hours (Optima L-100XP, Beckman Coulter). The 
pellet is washed with PBS and centrifuged again at 100,000g for 2 hours. 
The resuspended cell membrane vesicles are extruded through 400-nm 
polycarbonate membranes (Millipore) and stored at −80°C.
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Hemagglutination inhibition assay
The samples are diluted in 25 l of PBS twofold in a U-shaped 96-well 
plate. Twenty-five microliters of IAV solution (in PBS, containing 
4 HA units) is mixed with the samples by pipetting and incubated 
for 30 min at room temperature. Afterward, 50 l of 1% chicken 
RBCs is added to each well and incubated for another 30 min at room 
temperature. The hemagglutination is observed by tilting the plates. 
The sample concentration of the last well showing inhibition of 
hemagglutination is recorded as the binding constant KiHAI.
TIRF microscopy
TIRF microscopy is used to quantify the interaction of single, R18- 
labeled IAV with different glycostructures embedded in SLBs with 
different compositions, as described (19). The glycostructures orig-
inated from native RBCm vesicles, Zan-conjugated lipids, or both. 
This method provides information about various properties of the 
IAV-membrane interaction, such as the attachment rate to the mem-
brane, IAV mobility, and off-rate distributions regarding the different 
membrane compositions. The conduction of measurements is shown 
in the Supplementary Materials.
Synthesis of spherical and bowl-like nanoparticles
First, the resorcinol-formaldehyde–coated SiO2 nanoparticle is syn-
thesized via a one-step reaction according to an earlier report with 
slight modifications (28). Briefly, 2.5 ml of ammonia aqueous solu-
tions [30 weight % (wt %)] is added into 100 ml of ethanol/water 
(v/v, 2/1) and stirred for 1 hour at room temperature. With vigorous 
stirring, 3 ml of TEOS (tetraethoxysilane) (19.2 mmol), 0.2 g of 
resorcinol (4.5 mmol), and 0.7 ml of formaldehyde solution (37 wt % 
in H2O; 9 mmol) are added sequentially. The reaction is ceased by 
10-min centrifugation at 10,000 rpm after 3, 6, and 24 hours, re-
spectively. The final products are washed five times with water and 
collected via 10-min centrifugation at 10,000 rpm and then lyo-
philized. The nanocomposites are carbonized at 600°, 700°, and 
800°C (5°C/min) for 1 hour with argon, respectively. The SiO2 core 
is then removed by etching in 2 M NaOH for 2 days at 60°C, and 
different types of hollow nanocarbons, including the spherical and 
bowl-like nano particles, can be obtained via 10-min centrifugation 
at 10,000 rpm and washed extensively by water. Afterward, the 
nanoparticles are carbonized again at 1100°C (5°C/min) for 1 hour 
with argon to fix the morphology.
Coating of RBCm onto the nanoparticle surface
The RBCm is coated onto the nanoparticle surface with horn soni-
cation (Sonopuls Ultrasonic Homogenizers HD 2200, BANDELIN 
electronic GmbH & Co. KG, Berlin, Germany) at 4°C for 30 min and 
then the RBCm-coated nanocarbons are isolated by centrifugation 
at 5000 rpm for 5 min and washed with PBS buffer. The morphology 
of the RBCm-coated nanoparticles is studied by scanning electron 
microscopy and TEM. For a better view of RBCm, the sample is 
stained with 1% sodium phosphotungstate before the measurement. 
The protein content is studied by the Pierce BCA assay kit (23225; 
Thermo Fisher Scientific, USA) according to the manual instructions. 
The RBCm coating weight ratio is then estimated by the protein con-
tents following the equation
  Coating ratio (wt % ) =  
Protein content (RBCm‐coated nanoparticle)
    ──────────────────────────
Protein content (RBCm)
 × 100% 
For SDS–polyacrylamide gel electrophoresis, 10 g of samples is 
loaded to 10% polyacrylamide (PAM) gel, and the gel is run at 200 V 
for 1 hour and then stained with 10% (v/v) Coomassie blue solution 
and then imaged by the ChemiDoc MP imaging system (Bio-Rad). 
The sialic acid content for the RBCm-coated nanocarbons is studied 
by Sialic Acid (NANA) Assay Kit (Abcam) according to the instruc-
tions by the provider.
Virus binding tests
For the Western blot test, 5 l of concentrated A/X31 (H3N2) virus 
solution (protein content, 0.72 mg/ml) is incubated with 15 l of solu-
tion with different nanoinhibitors (1 mg/ml) for 45 min at 37°C. 
Then, the mixture is centrifuged at 10,000 rpm for 10 min to collect 
the virus-bound nanoinhibitors. The precipitant is washed with PBS 
and loaded to a 10% PAM gel. After running at 200 V for 1 hour, the 
proteins are transferred onto the polyvinylidene difluoride mem-
brane, which is then blocked by 3 wt % of milk powder. The NP is 
marked by influenza A NP monoclonal antibody (Invitrogen) and 
horseradish peroxidase–conjugated secondary antibody (Invitrogen). 
Then, chemiluminescent detection is performed using Pierce ECL 
Western Blotting Substrate (Thermo Fisher Scientific). The intensi-
ties of the bands are analyzed by ImageJ.
Virus attachment and inhibition
To study virus attachment, 100 l of A/X31 (H3N2) solution (pro-
tein content, 0.73 mg/ml) is incubated with 10 l of 20 M octadecyl 
rhodamine B chloride (R18; Thermo Fisher Scientific) in PBS for 
45 min first. The free R18 is removed with a spinning column (3300 rpm, 
2 min; Protein A HP SpinTrap, GE Healthcare). Then, 10 l of labeled 
virus is incubated with a 90-l nanoinhibitor solution (100 g/ml) 
for 45 min at 37°C. The mixture is then incubated with MDCK-II 
cells on ice for 1 hour. The unbound virions are removed by wash-
ing with PBS. Afterward, the cells are stained with 4′,6-diamidino- 
2-phenylindole (DAPI) and visualized by fluorescence microscopy. 
For a quantitative analysis of virus attachment, the mixture of labeled 
virus and nanoinhibitor is incubated with 100,000 MDCK-II cells for 
1 hour, and then the unbounded virus is removed by centrifugation 
at 1500 rpm for 2 min. The cells are washed with PBS and analyzed 
by flow cytometry (CytoFLEX S, Beckman Coulter).
For the infection inhibition test, 0.2 × 106 plaque-forming units 
(PFU) of A/X31 (H3N2) virus is treated with the nanoinhibitors for 
45 min at 37°C and then incubated with MDCK-II cells. After 45 min, 
the cells are washed twice by PBS and cultured in DMEM [0.1% bovine 
serum albumin (BSA), streptomycin (1100 mg/ml), and penicillin 
(100 U/ml)]. After 24 hours, the cells are fixed with 4% formalde-
hyde and permeabilized with 0.5% Triton X-100. The infected cells 
are marked by influenza A NP monoclonal antibody (Invitrogen) 
and Alexa Fluor 594–coupled secondary antibody (Invitrogen). The 
cell nucleus is stained using DAPI. The infection is estimated by 
counting infected cells from at least 10,000 cells in total and expressed 
as the number of infected cells per 1000 cells.
Multicyclic viral replication inhibition test
MDCK-II cells are first infected with IAV at the multiplicity of in-
fection of 0.01 and cultured in an infection medium [DMEM, 0.1% 
BSA, 1% l-glutamine, 1% penicillin-streptomycin, and TPCK(N-tosyl-L- 
phenylalanine chloromethyl ketone)-trypsin (1 g/ml)] containing the 
nanoinhibitors for 24 hours. The viruses in the supernatants are then 
titered by plaque assay on MDCK-II cells and are expressed as PFU/ml.
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SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/1/eabd3803/DC1
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